Apex Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Apex Biotechnology.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	23.0%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Apex Biotechnology jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

TWSE:1733 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2024	1,891	105	271	291	1
6/30/2024	1,711	109	241	265	N/A
3/31/2024	1,691	109	294	315	N/A
12/31/2023	1,677	116	205	230	N/A
9/30/2023	1,775	144	95	121	N/A
6/30/2023	1,968	170	22	55	N/A
3/31/2023	2,159	172	-13	20	N/A
12/31/2022	2,244	182	-14	27	N/A
9/30/2022	2,297	220	25	72	N/A
6/30/2022	2,201	220	33	73	N/A
3/31/2022	2,077	214	16	54	N/A
12/31/2021	2,132	202	150	180	N/A
9/30/2021	2,025	154	284	311	N/A
6/30/2021	2,025	113	274	306	N/A
3/31/2021	2,070	117	298	340	N/A
12/31/2020	2,005	95	232	281	N/A
9/30/2020	2,217	143	276	333	N/A
6/30/2020	2,173	103	353	416	N/A
3/31/2020	2,186	104	269	324	N/A
12/31/2019	2,199	114	406	463	N/A
9/30/2019	2,052	-4	137	207	N/A
6/30/2019	2,142	83	159	241	N/A
3/31/2019	2,098	100	136	216	N/A
12/31/2018	2,044	95	-15	68	N/A
9/30/2018	1,996	177	92	150	N/A
6/30/2018	1,919	129	145	183	N/A
3/31/2018	1,841	142	N/A	164	N/A
12/31/2017	1,795	86	N/A	71	N/A
9/30/2017	1,692	-90	N/A	96	N/A
6/30/2017	1,617	-110	N/A	118	N/A
3/31/2017	1,706	-103	N/A	165	N/A
12/31/2016	1,763	3	N/A	298	N/A
9/30/2016	1,874	209	N/A	436	N/A
6/30/2016	1,941	316	N/A	394	N/A
3/31/2016	1,855	292	N/A	423	N/A
12/31/2015	1,847	262	N/A	472	N/A
9/30/2015	1,863	271	N/A	455	N/A
6/30/2015	1,821	224	N/A	405	N/A
3/31/2015	1,840	248	N/A	340	N/A
12/31/2014	1,789	273	N/A	268	N/A
9/30/2014	1,648	220	N/A	218	N/A
6/30/2014	1,674	209	N/A	121	N/A
3/31/2014	1,728	307	N/A	305	N/A
12/31/2013	1,829	371	N/A	485	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 1733's forecast earnings growth is above the savings rate (1%).

Ertrag vs. Markt: Insufficient data to determine if 1733's earnings are forecast to grow faster than the TW market

Hohe Wachstumserträge: Insufficient data to determine if 1733's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if 1733's revenue is forecast to grow faster than the TW market.

Hohe Wachstumseinnahmen: Insufficient data to determine if 1733's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 1733's Return on Equity is forecast to be high in 3 years time

Apex Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to NT$26.00

Recent updates

Now 21% overvalued

Insufficient new directors

Second quarter 2024 earnings: EPS exceeds analyst expectations

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology Corp. to Report Q2, 2024 Results on Aug 09, 2024

New minor risk - Market cap size

First quarter 2024 earnings released: EPS: NT$0.29 (vs NT$0.36 in 1Q 2023)

Upcoming dividend of NT$1.10 per share

Apex Biotechnology Corp. to Report Q1, 2024 Results on May 10, 2024

Apex Biotechnology Corp. Approves Cash Dividend for 2023, Payable on June 14, 2024

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released

Apex Biotechnology Corp., Annual General Meeting, Apr 30, 2024

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 18%

Second quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.29 in 2Q 2022)

Upcoming dividend of NT$1.40 per share at 4.8% yield

Full year 2022 earnings released: EPS: NT$1.82 (vs NT$2.03 in FY 2021)

Price target decreased to NT$26.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS NT$0.64 (vs NT$0.23 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.27 in 2Q 2020)

Upcoming dividend of NT$1.09 per share

First quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.12 in 1Q 2020)

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Full year 2020 earnings released: EPS NT$0.95 (vs NT$1.14 in FY 2019)

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Apex Biotechnology Corp., Annual General Meeting, May 28, 2021

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

New 90-day low: NT$22.40

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

New 90-day low: NT$23.70

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Third quarter 2020 earnings released: EPS NT$0.23

New 90-day low: NT$24.15

New 90-day low: NT$25.05

First half earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken